MedTrace Logo

A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions

NCT00992862 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2013-09-26

No results posted yet for this study

Summary

The purpose of this study is to compare the relative bioavailability of Moexipril HCl 15mg tablets (by Paddock Laboratories, Inc.) with that of Univasc® 15mg tablets (by Schwarz Pharma) following a single oral dose (1 x 15mg tablet) in healthy, adult subjects under fasting conditions.

Conditions

  • Healthy

Interventions

DRUG

Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.

DRUG

Univasc® 15mg Tablets

Sponsors & Collaborators

  • Paddock Laboratories, Inc.

    lead INDUSTRY

Principal Investigators

  • Kennedy, M.D. · Novum Pharmaceutical Research Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00992862 on ClinicalTrials.gov